The Institute for Clinical and Economic Review (ICER) on Thursday, April 11, released a draft scoping document for a planned review of treatments for rheumatoid arthritis (RA).
According to a press release, ICER’s assessment will include new data on RA treatments since its 2017 review.
“In addition to re-assessing each of the therapies included in that previous report, ICER will evaluate the approved biosimilar Inflectra® (infliximab-dyyb, Pfizer and Celltrion), as well as upadacitinib (AbbVie), which is currently under review by the FDA with an expected decision around August 2019,” ICER states in the release.
The document is open to public comments until May 1.
To read the draft scoping document, click here.